Patients who were either anti-TNF-naïve or had an elevated baseline CRP achieved higher rates of remission than the general study population. Inthisposthocanalysis,weexaminedwhetherpatientswhowereanti-TNFnaïveandhadanelevatedCRPatbaselinecouldachievehigherremissionrates thanthosepreviouslyreported. Methods: Data from CHARM, a 56-week, randomized, placebo-controlled trialofADAmaintenancetherapy,wereanalyzed.Allpatientsreceivedopenlabel ADA during a 4 week induction period and were then randomized to ADA(40mgweeklyoreveryotherweek[eow])orplacebofora52weekdou-ble-blindperiod.Inthisanalysis,clinicalremissionatweek56wasdetermined forrandomizedresponders(patientswhohadadecreaseinCDAI≥70atweek4 comparedwithbaseline)whowerenaïvetoprioranti-TNFtreatment,bybaselineCRPsubgroups(high:≥10mg/L,vs.low:<10mg/L),usingnon-responder imputation.RemissionratesforpatientstreatedwithweeklyoreowADAwere comparedwithratesforplacebo-treatedpatients,usingFisher'sexacttest. Results: ADAtreatment(weeklyoreow)resultedinstatisticallysignificantly greaterratesofclinicalremissionatweek56comparedwithplacebotreatment ineachCRPsubgroupofanti-TNF-naïvepatients (table) .Thepercentageof patientsinclinicalremissionwasgreaterinthehighCRPsubgroupforboth weeklyandeowADAtreatment. Conclusion: In the CHARM trial, anti-TNF-naïve patients with baseline CRP≥10mg/L experienced greater rates of clinical remission, regardless of ADAdosefrequency,comparedwithpatientswithbaselineCRP<10mg/L.
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